Yantai Dongcheng Pharmaceutical's Sino Siam Biotechnique Gets US FDA's EIR After Inspection
MT Newswires Live
Sep 14
Sino Siam Biotechnique Company, a subsidiary of Yantai Dongcheng Pharmaceutical Group (SHE:002675), has received the US Food and Drug Administration's establishment inspection report following a successful on-site inspection, according to a Shenzhen bourse filing on Saturday.
The US FDA conducted an on-site inspection of the unit from July 17 to July 18, and the unit passed the inspection with a 'No Action Indicated' classification and zero Form 483 observations.
Shares of the pharmaceutical company rose nearly 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.